**4 year surveillance (2017) –** [**Neuropathic pain in adults: pharmacological management in non-specialist settings (2013)**](https://www.nice.org.uk/guidance/cg173) **NICE guideline CG173**

**Stakeholder consultation comments form - proposal for ‘no update’**

Consultation on the proposal for ‘no update’ opens on: Thursday, 22 June 2017

Comments on proposal to be submitted: no later than Wednesday, 5 July 2017

|  |  |
| --- | --- |
| **Please enter the name of your registered stakeholder or respondent organisation below.**  Please use this form for submitting your comments to NICE.   1. Please put each new comment in a new row. 2. Please note – we cannot accept comments forms with attachments such as research articles, letters or leaflets. If we receive forms with attachments we will return them without reading the comments. If you resubmit the comments on a form without attachments, this must be by the consultation deadline. 3. If you wish to draw our attention to published studies, please supply the full reference. 4. NICE is unable to accept comments from non-registered organisations. If you wish your comments to be considered please register via the NICE website or contact the [registered stakeholder organisation](https://www.nice.org.uk/guidance/cg173/documents/stakeholder-list-2) that most closely represents your interests and pass your comments to them. | |
| Organisation name – Stakeholder or respondent  (if you are commenting as an individual rather than a registered stakeholder or respondent organisation, please leave blank): |  |
| Disclosure  Please disclose whether the organisation has any past or current, direct or indirect links to, or receives funding from, the tobacco industry. |  |
| Name of commentator: |  |

[Developing NICE guidelines: the manual](https://www.nice.org.uk/process/pmg20/chapter/1-introduction-and-overview) gives an overview of the processes used in surveillance reviews of NICE clinical guidelines.

| **ID** | **Questions** | **Overall response**  yes / no | **Comments**  Please insert each new comment in a new row |
| --- | --- | --- | --- |
| 1 | Do you agree with the proposal not to update the guideline? |  |  |
| 2 | Do you agree with the proposal to put the guideline on the static list? |  |  |
| 3 | Do you agree with the proposal to remove the research recommendation:  RR–02 Is response to pharmacological treatment predicted more reliably by underlying aetiology or by symptom characteristics? |  |  |
| 4 | Do you agree with the proposal to remove the research recommendation:  RR–04 What are the key factors, including additional care and support that influence participation and quality of life in people with neuropathic pain? |  |  |
| 5 | Do you agree with the proposal to remove the research recommendation:  RR–05 What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain? |  |  |
| 6 | Do you agree with the proposal to remove the research recommendation:  RR–06 Is there a potential for dependence associated with pharmacological agents for neuropathic pain? |  |  |
| 7 | Do you have any comments on areas excluded from the scope of the guideline? |  |  |
| 8 | Do you have any comments on equalities issues? |  |  |

Please add extra rows as needed, keeping the ID number consistent with the corresponding question.

**Please email this form to:** [**surveillance@nice.org.uk**](mailto:surveillance@nice.org.uk)

**Closing date: 5 July 2017**

**PLEASE NOTE:**

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, if NICE’s reasonable opinion is that the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.